Kyodo News PR Wire·
イネレクスゾ承認。BCG不応の高リスク筋層非浸潤性膀胱がん治療を変える新たな選択肢
イネレクスゾ®、製造販売承認を取得 BCG療法後に残存・再発した上皮内がんを有する高リスク筋層非浸潤性膀胱がんの治療を 変える可能性をもつ、新たな選択肢 イネレクスゾ®は、抗がん剤（ゲムシタビン塩酸塩...
Read releases like this the second they cross the wire.
1,400+ feeds from 80+ newswires in one live cockpit — saved searches, instant alerts, AI summaries. 72-hour free trial, no card required.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live on PPN World.
PPN Source →Shared via PPN World — real-time press release intelligence.